Welcome to our dedicated page for Neumora Therapeutics news (Ticker: NMRA), a resource for investors and traders seeking the latest updates and insights on Neumora Therapeutics stock.
Neumora Therapeutics Inc (NMRA) is a clinical-stage biopharmaceutical company advancing novel treatments for brain diseases through precision neuroscience. This page serves as the definitive source for NMRA-related news, offering investors and stakeholders timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access curated press releases and analysis covering key aspects of Neumora's operations, including progress reports on its depression therapy navacaprant (KOR antagonist), Alzheimer's agitation candidate NMRA-511 (V1aR antagonist), and preclinical M4 PAM programs. Our repository simplifies tracking of trial phases, partnership announcements, and scientific publications.
All content undergoes rigorous verification to ensure alignment with financial disclosure standards. Bookmark this page for efficient monitoring of NMRA's innovative work in neuropsychiatric and neurodegenerative disorder treatments. Check regularly for updates on pipeline advancements and corporate announcements that may impact research trajectories.
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company, will host a virtual R&D Day on October 27, 2025, at 8:00 a.m. ET. The event will showcase the company's pipeline of seven programs targeting novel mechanisms for prevalent diseases.
Key presentations will feature NMRA-215, a brain-penetrant NLRP3 inhibitor for obesity treatment, NMRA-511 Phase 1b data for Alzheimer's agitation, the M4 franchise (NMRA-861 and NMRA-898), and navacaprant, a Phase 3 kappa opioid receptor antagonist.
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company, has announced its participation in three major investor conferences in September 2025. The company, which focuses on developing therapeutics for prevalent diseases through seven distinct programs, will attend the Wells Fargo Healthcare Conference (Sept. 4), Morgan Stanley Global Healthcare Conference (Sept. 8), and H.C. Wainwright Global Investment Conference (Sept. 9).
Management will be available for one-on-one meetings at the Wells Fargo and Morgan Stanley events, while participating in a fireside chat at the H.C. Wainwright conference. The fireside chat will be webcast live and archived for 30 days on the company's website.
Neumora Therapeutics (NASDAQ: NMRA) reported Q2 2025 financial results and provided significant pipeline updates. The company ended Q2 with $217.6 million in cash, expected to fund operations into 2027. Key developments include initiating a Phase 1 SAD/MAD study for NMRA-861 in schizophrenia and prioritizing obesity as the lead indication for NMRA-215, their brain-penetrant NLRP3 inhibitor.
Financial results showed R&D expenses of $38.7 million (down from $48.6M in Q2 2024) and a net loss of $52.7 million (improved from $58.7M). The company anticipates six clinical data readouts over the next 18 months, including Phase 3 data for navacaprant in major depressive disorder and Phase 1b data for NMRA-511 in Alzheimer's disease agitation.
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company focused on brain disease treatments, will host its Q2 2025 earnings call on August 6, 2025 at 4:30 p.m. ET. The company, which maintains a pipeline of seven brain disease programs including three in clinical stages, will present financial results and provide a business update.
The event will be accessible via webcast through the company's website at www.neumoratx.com, with a replay available for 30 days post-event. Participants are encouraged to register for the conference call at least 10 minutes before the start time.
Neumora Therapeutics (Nasdaq: NMRA) has initiated a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-861, a highly potent and selective M4 positive allosteric modulator (PAM), in healthy adults and those with stable schizophrenia.
The drug candidate demonstrates potential best-in-class pharmacology and showed promising safety in pre-clinical studies with no convulsions observed across multiple species. The company expects to report Phase 1 data, including safety, tolerability, and pharmacokinetic results, in Q1 2026.
NMRA-861 aims to offer a differentiated treatment option for schizophrenia and other neuropsychiatric disorders, potentially providing improved therapeutic benefits compared to current antipsychotics and non-selective muscarinic agonists, with the possibility of once-daily dosing.
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company, has announced it will host a conference call and live webcast to discuss its first quarter 2025 financial results on Monday, May 12, 2025, at 4:30 p.m. ET.
The company, which maintains a pipeline of seven brain disease programs including two clinical-stage programs, will also provide a business update during the call. Interested participants can access the webcast through the events and presentations section of Neumora's website, with a replay available for up to 30 days after the event.
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company focused on brain disease treatments, has announced its upcoming presentation at the Leerink Global Healthcare Conference. The presentation is scheduled for Tuesday, March 11, 2025, at 10:00 a.m. ET in Miami, FL.
The company, which maintains a pipeline of seven clinical and pre-clinical brain disease programs, will make the presentation available via live webcast on their website's Events and Presentations section at www.neumoratx.com. The recording will remain accessible for up to 30 days following the event.
Neumora Therapeutics (NMRA) has reported its Q4 and full year 2024 financial results, highlighting key developments in its neuroscience pipeline. The company ended 2024 with $307.6 million in cash and equivalents, expected to fund operations into mid-2026.
Following analysis of KOASTAL-1 results, Neumora has optimized its KOASTAL-2 and -3 studies for major depressive disorder treatment, with topline data expected in Q1 and Q2 2026 respectively. The company has paused and plans to resume these studies in March 2025 with enhanced site selection and medical monitoring.
Key financial metrics for 2024 include R&D expenses of $200.9 million (up from $142.7 million in 2023) and G&A expenses of $62.5 million (up from $45.5 million). The company reported a net loss of $243.8 million for the full year 2024.
Neumora Therapeutics (NASDAQ: NMRA) announced significant leadership changes effective February 14, 2025. Paul L. Berns, co-founder and executive chair, will become CEO and chairman of the Board, replacing Henry Gosebruch. Joshua Pinto, Ph.D., will serve as president, Bill Aurora, Pharm.D., as chief operating and development officer, and Michael Milligan as chief financial officer.
The clinical-stage biopharmaceutical company has seven clinical and pre-clinical brain disease programs in its pipeline, with clinical data readouts expected from all three clinical-stage programs in 2025. A key highlight is the ongoing Phase 3 program with navacaprant in depression. The company focuses on developing novel treatments for brain diseases with therapeutically relevant targets and best-in-class pharmacology.
Neumora will host a conference call on March 3, 2025, to report Q4 and full-year 2024 financial results and provide a business update.
FAQ
What is the current stock price of Neumora Therapeutics (NMRA)?
What is the market cap of Neumora Therapeutics (NMRA)?
